Neuropace Stock Performance
| NPCE Stock | USD 9.06 0.02 0.22% |
The company secures a Beta (Market Risk) of 0.0052, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Neuropace's returns are expected to increase less than the market. However, during the bear market, the loss of holding Neuropace is expected to be smaller as well. At this point, Neuropace has a negative expected return of -0.0859%. Please make sure to verify Neuropace's kurtosis, as well as the relationship between the rate of daily change and price action indicator , to decide if Neuropace performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Neuropace has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound fundamental indicators, Neuropace is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return (0.22) | Five Day Return (4.63) | Year To Date Return (21.76) | Ten Year Return (63.70) | All Time Return (63.70) |
1 | Disposition of 237 shares by Martha Morrell of Neuropace at 10.94 subject to Rule 16b-3 | 04/22/2025 |
2 | Disposition of 237 shares by Rebecca Kuhn of Neuropace at 10.94 subject to Rule 16b-3 | 04/23/2025 |
3 | NeuroPace First Quarter 2025 Earnings Beats Expectations | 05/15/2025 |
4 | Disposition of 3051 shares by Martha Morrell of Neuropace at 17.99 subject to Rule 16b-3 | 05/20/2025 |
5 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE | 05/28/2025 |
6 | Disposition of 1338 shares by Martha Morrell of Neuropace at 13.54 subject to Rule 16b-3 | 06/03/2025 |
7 | NeuroPace, Inc. Backed by Cantor Fitzgerald Following Physician Survey | 06/17/2025 |
8 | INVESTOR ALERT Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of NeuroPace, Inc. - NPCE | 06/18/2025 |
9 | Acquisition by Fischer Frank M of 2281 shares of Neuropace at 10.41 subject to Rule 16b-3 | 06/20/2025 |
10 | NeuroPace Announces Strategic CFO Transition NPCE Stock News | 06/24/2025 |
11 | NeuroPace Inc Trading Down 3.93 percent on Jun 27 | 06/27/2025 |
12 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. ... | 07/01/2025 |
13 | Acquisition by Geiger Uri of 2337 shares of Neuropace at 4.49 subject to Rule 16b-3 | 07/11/2025 |
14 | Acquisition by Kumar Rakhi of 1247 shares of Neuropace at 12.02 subject to Rule 16b-3 | 07/17/2025 |
| Begin Period Cash Flow | 18.2 M | |
| Total Cashflows From Investing Activities | 9 M |
Neuropace | Build AI portfolio with Neuropace Stock |
Neuropace Relative Risk vs. Return Landscape
If you would invest 1,054 in Neuropace on April 20, 2025 and sell it today you would lose (148.00) from holding Neuropace or give up 14.04% of portfolio value over 90 days. Neuropace is currently does not generate positive expected returns and assumes 5.4569% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Neuropace, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neuropace Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuropace's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neuropace, and traders can use it to determine the average amount a Neuropace's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0157
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NPCE |
Estimated Market Risk
| 5.46 actual daily | 48 52% of assets are more volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Neuropace is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neuropace by adding Neuropace to a well-diversified portfolio.
Neuropace Fundamentals Growth
Neuropace Stock prices reflect investors' perceptions of the future prospects and financial health of Neuropace, and Neuropace fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neuropace Stock performance.
| Return On Equity | -1.28 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | 313.56 M | ||||
| Shares Outstanding | 32.8 M | ||||
| Price To Book | 12.64 X | ||||
| Price To Sales | 3.52 X | ||||
| Revenue | 79.91 M | ||||
| Gross Profit | 63.08 M | ||||
| EBITDA | (16.57 M) | ||||
| Net Income | (27.14 M) | ||||
| Cash And Equivalents | 92.41 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 73.34 M | ||||
| Debt To Equity | 1.08 % | ||||
| Current Ratio | 9.86 X | ||||
| Book Value Per Share | 0.74 X | ||||
| Cash Flow From Operations | (17.95 M) | ||||
| Earnings Per Share | (0.82) X | ||||
| Market Capitalization | 297.15 M | ||||
| Total Asset | 94.65 M | ||||
| Retained Earnings | (530.95 M) | ||||
| Working Capital | 66.18 M | ||||
About Neuropace Performance
By analyzing Neuropace's fundamental ratios, stakeholders can gain valuable insights into Neuropace's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neuropace has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neuropace has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 234.57 | 273.68 | |
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.27) | (0.29) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (3.39) | (3.22) |
Things to note about Neuropace performance evaluation
Checking the ongoing alerts about Neuropace for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neuropace help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neuropace generated a negative expected return over the last 90 days | |
| Neuropace has high historical volatility and very poor performance | |
| Neuropace has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 79.91 M. Net Loss for the year was (27.14 M) with profit before overhead, payroll, taxes, and interest of 63.08 M. | |
| Neuropace currently holds about 92.41 M in cash with (17.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| Neuropace has a poor financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Freedom Broker initiates coverage on Electromed stock with Buy rating By Investing.com - Investing.com South Africa |
- Analyzing Neuropace's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neuropace's stock is overvalued or undervalued compared to its peers.
- Examining Neuropace's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neuropace's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neuropace's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neuropace's stock. These opinions can provide insight into Neuropace's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |